Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1999;99:2396-2401

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matter, C. M.
Right arrow Articles by Hess, O. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matter, C. M.
Right arrow Articles by Hess, O. M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*NITRIC OXIDE
*NITROGLYCERIN
Related Collections
Right arrow Congestive
Right arrow Cardiovascular Pharmacology
Right arrow Hypertrophy

(Circulation. 1999;99:2396-2401.)
© 1999 American Heart Association, Inc.


Clinical Investigation and Reports

Effect of NO Donors on LV Diastolic Function in Patients With Severe Pressure-Overload Hypertrophy

Christian M. Matter, MD; Lazar Mandinov, MD, PhD; Philipp A. Kaufmann, MD; Giuseppe Vassalli, MD; Zihua Jiang, PhD; Otto M. Hess, MD

From the Division of Cardiology, University Hospitals Zurich and Bern, Switzerland.

Correspondence to Otto M. Hess, MD, Professor of Cardiology, Swiss Heart Center, University Hospital, CH-3010 Bern, Switzerland. E-mail otto.martin.hess{at}insel.ch

Background—Previous experimental studies have shown that nitric oxide (NO) modulates cardiac function by an abbreviation of systolic contraction and an enhancement of diastolic relaxation. However, the response to NO donors of patients with severe pressure-overload hypertrophy and diastolic dysfunction is unknown.

Methods and Results—Intracoronary NO donors were given to 17 patients with severe aortic stenosis. A dose-response curve was obtained with nitroglycerin (30, 90, and 150 µg) in 11 patients and sodium nitroprusside (1, 2, and 4 µg/min) in 6. Left ventricular (LV) high-fidelity pressure measurements with simultaneous LV angiograms were performed at baseline and after the maximal dose of NO. The dose-response curve for intracoronary NO donors showed a marked fall in LV end-diastolic pressure, from 23 to 14 mm Hg (-39%; P<0.0001), whereas LV peak systolic pressure fell only slightly, from 206 to 196 mm Hg (-4%; P<0.01). End-diastolic chamber stiffness decreased from 0.12 to 0.07 mm Hg/mL (P<0.0001) and end-systolic stiffness from 1.6 to 1.3 mm Hg/mL (P<0.01). Heart rate, right atrial pressure, LV ejection fraction, the time constant of isovolumic pressure decay ({tau}), and LV filling rates remained unchanged.

Conclusions—In patients with severe pressure-overload hypertrophy, intracoronary NO donors exert a marked decrease in LV end-diastolic pressure without affecting LV systolic pump function. Thus, the hypertrophied myocardium appears to be particularly susceptible to NO donors, with a marked improvement in diastolic function.


Key Words: nitric oxide • nitroglycerin • sodium nitroprusside • hypertrophy • diastole




This article has been cited by other articles:


Home page
Physiol. Rev.Home page
J.-L. Balligand, O. Feron, and C. Dessy
eNOS Activation by Physical Forces: From Short-Term Regulation of Contraction to Chronic Remodeling of Cardiovascular Tissues
Physiol Rev, April 1, 2009; 89(2): 481 - 534.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
W. H. Wilson Tang, W. Tong, K. Shrestha, Z. Wang, B. S. Levison, B. Delfraino, B. Hu, R. W. Troughton, A. L. Klein, and S. L. Hazen
Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure
Eur. Heart J., October 2, 2008; 29(20): 2506 - 2513.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
G. Ruiz-Hurtado, M. Fernandez-Velasco, M. Mourelle, and C. Delgado
LA419, a Novel Nitric Oxide Donor, Prevents Pathological Cardiac Remodeling in Pressure-Overloaded Rats Via Endothelial Nitric Oxide Synthase Pathway Regulation
Hypertension, December 1, 2007; 50(6): 1049 - 1056.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Seddon, A. M. Shah, and B. Casadei
Cardiomyocytes as effectors of nitric oxide signalling
Cardiovasc Res, July 15, 2007; 75(2): 315 - 326.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Z. B. Popovic, U. N. Khot, G. M. Novaro, F. Casas, N. L. Greenberg, M. J. Garcia, G. S. Francis, and J. D. Thomas
Effects of sodium nitroprusside in aortic stenosis associated with severe heart failure: pressure-volume loop analysis using a numerical model
Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H416 - H423.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
W. J. Paulus and J. G. F. Bronzwaer
Nitric oxide's role in the heart: control of beating or breathing?
Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H8 - H13.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
S. Nodari, M. Metra, and L. D. Cas
{beta}-Blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol
Eur J Heart Fail, October 1, 2003; 5(5): 621 - 627.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
H. Post, C. d'Agostino, V. Lionetti, M. Castellari, E. Y Kang, M. Altarejos, X. Xu, T. H Hintze, and F. A Recchia
Reduced Left Ventricular Compliance and Mechanical Efficiency after Prolonged Inhibition of NO Synthesis in Conscious Dogs
J. Physiol., October 1, 2003; 552(1): 233 - 239.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
M. Scorsin, A. Mebazaa, N. A. Attar, B. Medini, J. Callebert, R. Raffoul, R. Ramadan, J. M. Maillet, A. Ruffenach, F. Simoneau, et al.
Efficacy of esmolol as a myocardial protective agent during continuous retrograde blood cardioplegia
J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 1022 - 1029.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. G. F. Bronzwaer, C. Heymes, C. A. Visser, and W. J. Paulus
Myocardial fibrosis blunts nitric oxide synthase-related preload reserve in human dilated cardiomyopathy
Am J Physiol Heart Circ Physiol, January 1, 2003; 284(1): H10 - H16.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
P B Massion and J-L Balligand
Modulation of cardiac contraction, relaxation and rate by the endothelial nitric oxide synthase (eNOS): lessons from genetically modified mice
J. Physiol., January 1, 2003; 546(1): 63 - 75.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
A. Cohen-Solal
Diastolic heart failure: myth or reality?
Eur J Heart Fail, August 1, 2002; 4(4): 395 - 400.
[Full Text] [PDF]


Home page
ChestHome page
S. Mak, E. R. Azevedo, P. P. Liu, and G. E. Newton
Effect of Hyperoxia on Left Ventricular Function and Filling Pressures in Patients With and Without Congestive Heart Failure
Chest, August 1, 2001; 120(2): 467 - 473.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. M Bryant, C. E Sears, L. Rigg, D. A Terrar, and B. Casadei
Nitric oxide does not modulate the hyperpolarization-activated current, If, in ventricular myocytes from spontaneously hypertensive rats
Cardiovasc Res, July 1, 2001; 51(1): 51 - 58.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
W. Grossman
Defining Diastolic Dysfunction
Circulation, May 2, 2000; 101(17): 2020 - 2021.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
L. Mandinov, F. R. Eberli, C. Seiler, and O. M. Hess
Diastolic heart failure
Cardiovasc Res, March 1, 2000; 45(4): 813 - 825.
[Abstract] [Full Text] [PDF]